Biotech Rally Fueled by FDA Win: Multiple Players Gain Ground in Extended Trading

Healthcare and biotech sector experienced a bullish session during after-hours trading on Monday, with several key players registering impressive gains. The momentum was largely anchored by Novo Nordisk A/S (NVO), which jumped 9.48% to reach $52.66 following the FDA’s approval of its once-daily Wegovy pill—a groundbreaking oral GLP-1 therapeutic for obesity management in the United States.

Novo Nordisk Leads the Charge with Historic Approval

Novo Nordisk’s $4.56 price surge reflects investor enthusiasm over Wegovy’s dual indication: weight loss through combined reduced-calorie diet and exercise protocols, and cardiovascular risk reduction for obese or overweight patients with established heart disease. This approval represents the first oral GLP-1 option available in the U.S. market, differentiating it from injectable competitors and potentially reshaping the obesity treatment landscape.

Sector Breadth Shows Mixed Drivers

Beyond Novo Nordisk’s headline-driven advance, other biotech names captured market interest through different catalysts. Neumora Therapeutics, Inc. (NMRA) climbed 16.02% to $2.10 despite the absence of fresh company developments, suggesting the gains were driven by broader sector tailwinds and speculative positioning. BioRestorative Therapies, Inc. (BRTX) added 6.90% to $1.24, carrying forward positive sentiment from its mid-November FDA Type B meeting grant for BRTX-100’s accelerated biologics pathway targeting chronic lumbar disc disease—a December meeting is expected to provide further clarity on the accelerated pathway potential.

Development-Stage Updates Continue to Support Valuations

RenovoRx, Inc. (RNXT) registered a 4.44% increase to $0.94 after-hours, with investors referencing the company’s upcoming January presentation at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium 2026, where Phase III TIGeR-PaC trial pharmacokinetic and pharmacodynamic sub-study results will be shared.

IDEAYA Biosciences, Inc. (IDYA) advanced 6.49% to $37.81, building on momentum from its recently completed Phase 2/3 OptimUM-02 trial enrollment of 435 patients testing darovasertib combined with Pfizer’s crizotinib for metastatic uveal melanoma. First-quarter 2026 progression-free survival data could support an accelerated U.S. approval filing.

Diversification Within Healthcare Technology

Healthcare Triangle, Inc. (HCTI) posted a 6.72% after-hours gain to $1.43, with the advance reflecting confidence in its December 10 announcement of an Advance Agreement for acquiring Spain-based AI-driven customer experience platforms. The strategic move positions the company to strengthen its footprint in AI-powered patient and customer engagement—a growing intersection of healthcare technology and data management that extends beyond traditional lumbar and orthopedic verticals into comprehensive patient interaction solutions.

Alphatec Holdings, Inc. (ATEC), the spine surgery technology provider, posted more modest 2.80% gains to $21.28, indicating steady confidence in the orthopedic device sector despite the absence of new Monday announcements.

The collective strength across multiple subsectors underscores investor appetite for biotech exposure, whether driven by regulatory catalysts, trial progression, or strategic positioning within emerging healthcare technology domains.